Topical Finasteride 0.25% in HPCH Spray for Androgenetic Alopecia: A Single-Center Retrospective Study

This randomized, double-blind, placebo-controlled phase III trial found that a 24-week treatment with topical finasteride significantly increased hair growth and was well-tolerated in Chinese men with androgenetic alopecia compared to placebo.

This review suggests that combining PRP with minoxidil may be more effective for promoting hair growth in androgenetic alopecia than using either treatment alone, although study variations limit definitive conclusions.

This study found a high discontinuation rate of topical minoxidil among patients with androgenetic alopecia, largely influenced by short treatment duration, lack of efficacy, and adverse effects.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study found that androgenetic alopecia is significantly associated with moderate impairment of health-related quality of life and emotions, but not with depressive symptoms.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This study found that low-level laser therapy was the most effective non-surgical treatment for androgenetic alopecia, although the overall quality of evidence supporting various therapies was generally low.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This review discusses the clinical, epidemiological, and pathophysiological aspects of female pattern hair loss, reporting no new research findings.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

In this study, researchers observed that follicular microinflammation significantly contributes to the early stages of male androgenetic alopecia, potentially leading to perifollicular fibrosis and follicle destruction as the condition progresses.

This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.